SCHEDULE: Coastlands Capital Acquires 16.5% Stake in Eloxx

Coastlands Capital LP and its affiliates have disclosed a significant 16.51% passive ownership stake in Eloxx Pharmaceuticals following the exercise of pre-funded warrants.

Summary

• Coastlands Capital LP and associated entities reported a beneficial ownership of 1,250,000 shares of Eloxx Pharmaceuticals common stock.
• The reporting persons represent a 16.51% ownership stake in the company.
• The ownership calculation is based on 5,071,935 shares outstanding as of March 12, 2026, plus 2,500,000 shares issued on April 27, 2026, upon the exercise of pre-funded warrants.
• The filing is a Schedule 13G, indicating a passive investment intent rather than an attempt to influence or change control of the issuer.
• The reporting group includes Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as positive institutional validation. A 16.5% stake from a professional investment group suggests strong conviction in the company's underlying value, despite the dilutive impact of the warrant exercise.

Positives

• Significant institutional validation from Coastlands Capital with a double-digit percentage stake.
• The exercise of pre-funded warrants indicates a commitment of capital and long-term interest in the company's equity.
• The passive nature of the filing suggests management currently has the support of its largest shareholders.

Negatives

• The issuance of 2,500,000 new shares on April 27, 2026, represents significant equity dilution for existing shareholders.
• High concentration of ownership (16.51%) in a single investment group could lead to liquidity issues or outsized price impact if the group decides to exit.

Risks

• Potential for further dilution as the reporting persons hold additional pre-funded warrants, though currently limited by a 4.99% beneficial ownership cap on further exercises.
• Market volatility may be exacerbated by the high concentration of shares held by a single entity.
• The company's small share count (approximately 7.57 million shares) makes it susceptible to significant price swings on low volume.

Future Outlook

The reporting persons have certified that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. Future filings will be required if the ownership stake changes by more than 1% or if the intent shifts from passive to active.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, large passive stakes from specialized investment firms like Coastlands Capital often precede major clinical milestones or serve as a stabilizing force during capital-intensive research phases.

Comparison to Industry Standards

• A 16.51% stake is significantly higher than the typical 5-10% institutional entry point for micro-cap biotech companies.
• The use of pre-funded warrants is a common financing structure in the biotech industry to provide immediate capital while deferring the formal issuance of shares until specific conditions are met.

Stakeholder Impact

• Existing shareholders experience dilution due to the 2.5 million new shares issued.
• The company benefits from increased capital and a strong institutional shareholder base.

Next Steps

• Monitor for any amendments to the Schedule 13G if the reporting group increases or decreases its position.
• Watch for company announcements regarding the use of proceeds from the warrant exercises.

Key Dates

Recommendation

The significant institutional stake is a positive signal, but the recent dilution and the passive nature of the investment suggest that investors should wait for further clinical or operational catalysts before increasing positions.

Keywords

Eloxx Pharmaceuticals, Coastlands Capital, Schedule 13G, Passive Investment, Pre-funded Warrants, Matthew D. Perry, Biotechnology, Beneficial Ownership